Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a prominent player in the field of T-cell immunotherapy, focusing on developing treatments for cancer and autoimmune diseases. The company leverages its innovative allogeneic Epstein-Barr virus (EBV) T-cell platform to create transformative therapies. Operating within the Zacks Medical - Biomedical and Genetics industry, Atara competes with other biotech firms in advancing medical treatments.
On March 7, 2025, Atara reported an earnings per share (EPS) of -$1.19, significantly outperforming the estimated -$3.82. This result marks a substantial improvement from the previous year's loss of $14 per share, as highlighted by Zacks. The company's performance led to an earnings surprise of 68.85%, showcasing its ability to exceed market expectations.
In terms of revenue, Atara reported approximately $32.75 million for the quarter ending December 2024, surpassing the estimated $20.58 million. This represents a 150.02% increase over the Zacks Consensus Estimate and a significant rise from the $4.25 million reported in the same quarter the previous year. Atara has consistently exceeded consensus revenue estimates in three of the last four quarters.
Despite these positive results, Atara faces financial challenges. The company's price-to-sales ratio is approximately 0.40, indicating that its market value is less than its sales. The enterprise value to sales ratio is about 0.43, reflecting a similar valuation when considering debt and cash. Additionally, Atara's earnings yield is negative at -18.69%, and its debt-to-equity ratio is -0.55, suggesting potential financial instability.
Atara's current ratio stands at 0.59, indicating potential liquidity challenges in meeting short-term obligations. Despite these financial hurdles, the company remains focused on enhancing the financial value of its EBVALLO product and achieving key milestones in 2025.
